O. Saunders

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger et al. · Journal of Clinical Oncology · 2007 · 302 citations

Pharmacy, Oncology, Pharmacology +17

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

Hester van Cruijsen, Emile E. Voest, Cornelis J.A. Punt et al. · European Journal of Cancer · 2010 · 54 citations

Medicine, Oncology, Pharmacology +13

A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results

David Cunningham, Rlc Wong, G D’Haens et al. · Journal of Clinical Oncology · 2008 · 29 citations

Medicine, Oncology, Pharmacology +17

R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study

R. Hart, Darren Burns, Bram Ramaekers et al. · PharmacoEconomics · 2020 · 15 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +14

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

Philippe Moreau, Katja Weisel, Kevin Song et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 11 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16